Last reviewed · How we verify

Orient Pharma Co., Ltd. — Portfolio Competitive Intelligence Brief

Orient Pharma Co., Ltd. pipeline: 0 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Placebo First, then ORADUR® Placebo First, then ORADUR® phase 3 Opioid partial agonist Opioid receptors Pain management
1PC111 1PC111 phase 3 PI3K inhibitor PI3K Oncology
1PC002 1PC002 phase 3 PI3K inhibitor PI3K Oncology
ORADUR®-Methylphenidate ORADUR®-Methylphenidate phase 3 Sympathomimetic amine; central nervous system stimulant Dopamine transporter (DAT); Norepinephrine transporter (NET) Neurology / Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Addpharma Inc. · 1 shared drug class
  2. Aevi Genomic Medicine, LLC, a Cerecor company · 1 shared drug class
  3. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  4. Amorphical Ltd. · 1 shared drug class
  5. Angitia Incorporated Limited · 1 shared drug class
  6. Applied Biology, Inc. · 1 shared drug class
  7. Aptarion Biotech AG · 1 shared drug class
  8. AB Science · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Orient Pharma Co., Ltd.:

Cite this brief

Drug Landscape (2026). Orient Pharma Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/orient-pharma-co-ltd. Accessed 2026-05-15.

Related